High-risk human papillomavirus testing is superior to visual inspection with acetic acid in cervical cancer screening of Kenyan and Ugandan women living with HIV

Background: The current model of screening by visual inspection with acetic acid (VIA) has not led to a reduction in cervical cancer among sub-Saharan women living with human immunodeficiency virus (HIV)/aquired immunodeficiency syndrome (AIDS)(WLWH), and screening using high-risk human papillomavirus (HR-HPV) testing has not been adequately studied in WLWH. Methods: Kenyan women aged 21 to 60 years provided self-collected vaginal swabs for HR-HPV testing (Cobas HPV® Assay), all women then underwent VIA. All WLWH (n = 120) were scheduled for cervical biopsy. Testing parameters were estimated for HR-HPV and VIA for detection of cervical intraepithelial neoplasia (CIN) grades 2 or 3, and CIN grade 3). Results: HR-HPV was detected in 49 of 120 (40.8%) WLWH. Cervical biopsy revealed CIN2/3 in 14 WLWH (11.7%) and CIN3 in 6 (5.0%). VIA was abnormal in 17 WLWH (14.2%). The sensitivities of HR-HPV testing for CIN2/3 and CIN3 detection were 78.6% and 100%, respectively, and were superior to VIA (57.1% and 50%, respectively). All 6 cases of CIN3 occurred among WLWH with a positive HR-HPV test; VIA was abnormal in 3 of these women and normal in 3. Conclusions: Future cervical cancer screening strategies for WLWH should utilize HR-HPV testing of self-collected swabs. Compared to the high sensitivity of HR-HPV testing, VIA performed poorly for CIN3 detection.

HPV testing; Cervical cancer screening; Women living with HIV

[1] Lin S, Gao K, Gu S, You L, Qian S, Tang M, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years. Cancer. 2021; 127: 4030–4039.

[2] Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the who Global Cervical Cancer Elimination Initiative. The Lancet Global Health. 2023; 11: e197–e206.

[3] Dzinamarira T, Moyo E, Dzobo M, Mbunge E, Murewanhema G. Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services. International Journal of Gynecological Cancer. 2023; 33: 592–597.

[4] Mboumba Bouassa R, Prazuck T, Lethu T, Jenabian M, Meye J, Bélec L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Review of Anti-Infective Therapy. 2017; 15: 613–627.

[5] Mulongo M, Chibwesha CJ. Prevention of cervical cancer in low-resource African settings. Obstetrics and Gynecology Clinics of North America. 2022; 49: 771–781.

[6] Ramogola-Masire D, Luckett R, Dreyer G. Progress and challenges in human papillomavirus and cervical cancer in southern Africa. Current Opinion in Infectious Diseases. 2022; 35: 49–54.

[7] Huang J, Deng Y, Boakye D, Tin MS, Lok V, Zhang L, et al. Global distribution, risk factors, and recent trends for cervical cancer: a worldwide country-level analysis. Gynecologic Oncology. 2022; 164: 85–92.

[8] Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. Journal of the National Cancer Institute. 1999; 91: 506–511.

[9] Wallin K, Wiklund F, Ångström T, Bergman F, Stendahl U, Wadell G, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. The New England Journal of Medicine. 1999; 341: 1633–1638.

[10] Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, et al.; CBCSP-HPV study group. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. Journal of the National Cancer Institute. 2011; 103: 1387–1396.

[11] Wan Z, Zhao J, Xu L, Sun P, Shuai P, Li K, et al. Global and regional estimates of cervical cancer burden associated with human immunodeficiency virus infection from 1990 to 2019. Journal of Medical Virology. 2023; 95: e28891.

[12] Maina WK, Kim AA, Rutherford GW, Harper M, K’Oyugi BO, Sharif S, et al. Kenya AIDS indicator surveys 2007 and 2012. Journal of Acquired Immune Deficiency Syndromes. 2014; 66: S130–S137.

[13] Uganda AIDS Commission. Uganda HIV/AIDS country progress report July 2016–June 2017. 2017. Available at: https://www.unaids.org/sites/default/files/country/documents/UGA_2018_countryreport.pdf (Accessed: 27 February 2025).

[14] Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018; 32: 795–808.

[15] Sharma K, Machalek DA, Toh ZQ, Amenu D, Muchengeti M, Ndlovu AK, et al. No woman left behind: achieving cervical cancer elimination among women living with HIV. The Lancet HIV. 2023; 10: e412–e420.

[16] Kelly HA, Sawadogo B, Chikandiwa A, Segondy M, Gilham C, Lompo O, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS. AIDS. 2017; 31: 273–285.

[17] Ermel A, Tong Y, Tonui P, Orang’o O, Muthoka K, Wong N, et al. Longer duration of anti-retroviral therapy is associated with decreased risk of human papillomaviruses detection in Kenyan women living with HIV. International Journal of STD & AIDS. 2021; 32: 1212–1220.

[18] Adler DH. The impact of HAART on HPV-related cervical disease. Current HIV Research. 2010; 8: 493–497.

[19] Khozaim K, Orang’o E, Christoffersen‐Deb A, Itsura P, Oguda J, Muliro H, et al. Successes and challenges of establishing a cervical cancer screening and treatment program in western Kenya. International Journal of Gynecology & Obstetrics. 2014; 124: 12–18.

[20] Ndejjo R, Mukama T, Musinguzi G, Halage AA, Ssempebwa JC, Musoke D. Women’s intention to screen and willingness to vaccinate their daughters against cervical cancer—a cross sectional study in eastern Uganda. BMC Public Health. 2017; 17: 255.

[21] Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. Bulletin of the World Health Organization. 2001; 79: 954–962.

[22] Mabeya H, Khozaim K, Liu T, Orango O, Chumba D, Pisharodi L, et al. Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus—infected women in Western Kenya. Journal of Lower Genital Tract Disease. 2012; 16: 92–97.

[23] Garland SM, Iftner T, Cuschieri K, Kaufmann AM, Arbyn M, de Sanjose S, et al. IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: quality assurance and quality control issues. Journal of Clinical Virology. 2023; 159: 105349.

[24] Kuhn L, Denny L. The time is now to implement HPV testing for primary screening in low resource settings. Preventive Medicine. 2017; 98: 42–44.

[25] Tota JE, Bentley J, Blake J, Coutlée F, Duggan MA, Ferenczy A, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Preventive Medicine. 2017; 98: 5–14.

[26] Nakalembe M, Makanga P, Kambugu A, Laker‐Oketta M, Huchko MJ, Martin J. A public health approach to cervical cancer screening in Africa through community‐based self‐administered HPV testing and mobile treatment provision. Cancer Medicine. 2020; 9: 8701–8712.

[27] Hammer A, Demarco M, Campos N, Befano B, Gravitt PE, Cheung L, et al. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: results of the 15‐year cervical cancer screening experience at Kaiser Permanente Northern California. International Journal of Cancer. 2020; 147: 1612–1620.

[28] Davey DD. American Cancer Society signals transition in cervical cancer screening from cytology to HPV tests. Cancer Cytopathology. 2021; 129: 259–261.

[29] Daponte N, Valasoulis G, Michail G, Magaliou I, Daponte AI, Garas A, et al. HPV-based self-sampling in cervical cancer screening: an updated review of the current evidence in the literature. Cancers. 2023; 15: 1669.

[30] Ogilvie G, Nakisige C, Huh WK, Mehrotra R, Franco EL, Jeronimo J. Optimizing secondary prevention of cervical cancer: recent advances and future challenges. International Journal of Gynecology & Obstetrics. 2017; 138: 15–19.

[31] Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV‐based primary screening to liquid‐based cytology for cervical cancer. International Journal of Cancer. 2017; 140: 440–448.

[32] World Health Organization. New recommendations for screening and treatment to prevent cervical cancer. 2021. Available at: https://www.who.int/news/item/06-07-2021-new-recommendations-for-screening-and-treatment-to-prevent-cervical-cancer (Accessed: 27 February 2025).

[33] Bigoni J, Gundar M, Tebeu PM, Bongoe A, Schafer S, Fokom-Domgue J, et al. Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women. International Journal of Cancer. 2015; 137: 127–134.

[34] Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. Journal of Clinical Virology. 2016; 7: S49–S55.

[35] Chung MH, McKenzie KP, De Vuyst H, Richardson BA, Rana F, Pamnani R, et al. Comparing Papanicolau smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy. AIDS. 2013; 27: 2909–2919.

[36] Luckett R, Mogowa N, Li HJ, Erlinger A, Hacker MR, Esselen K, et al. Performance of two-stage cervical cancer screening with primary high-risk human papillomavirus testing in women living with human immunodeficiency virus. Obstetrics & Gynecology. 2019; 134: 840–849.

[37] Tong Y, Orang’o E, Nakalembe M, Tonui P, Itsura P, Muthoka K, et al. The East Africa Consortium for human papillomavirus and cervical cancer in women living with HIV/AIDS. Annals of Medicine. 2022; 54: 1202–1211.

[38] Tranberg M, Jensen JS, Bech BH, Blaakær J, Svanholm H, Andersen B. Good concordance of HPV detection between cervico-vaginal self-samples and general practitioner-collected samples using the Cobas 4800 HPV DNA test. BMC Infectious Diseases. 2018; 18: 348.

[39] Kremer WW, van Zummeren M, Breytenbach E, Richter KL, Steenbergen RDM, Meijer CJLM, et al. The use of molecular markers for cervical screening of women living with HIV in South Africa. AIDS. 2019; 33: 2035–2042.

[40] Ssedyabane F, Ngonzi J, Tusubira D, Nambi Najjuma J, Kajabwangu R, Okeny C, et al. Association between serum P16ink4a concentration and CIN and cervical cancer among women attending a cervical cancer clinic in western Uganda: a case control study. Gynecologic Oncology Reports. 2024; 53: 101388.

[41] Asangbeh-Kerman SL, Davidović M, Taghavi K, Kachingwe J, Rammipi KM, Muzingwani L, et al. Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies. BMC Public Health. 2022; 22: 1530.

[42] Boily M, Barnabas RV, Rönn MM, Bayer CJ, van Schalkwyk C, Soni N, et al. Estimating the effect of HIV on cervical cancer elimination in South Africa: comparative modelling of the impact of vaccination and screening. EClinicalMedicine. 2022; 54: 101754.

[43] Myers KO, Ahmed NU. The role of HIV in the progression through the stages of the human papillomavirus to cervical cancer pathway. AIDS Reviews. 2019; 20: 94–103.

[44] Chambuso RS, Shadrack S, Lidenge SJ, Mwakibete N, Medeiros RM. Influence of HIV/AIDS on cervical cancer: a retrospective study from Tanzania. Journal of Global Oncology. 2017; 3: 72–78.

[45] Kelly H, Jaafar I, Chung M, Michelow P, Greene S, Strickler H, et al. Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022; 53: 101645.

[46] Luckett R, Ramogola-Masire D, Gompers A, Moraka N, Moyo S, Sedabadi L, et al. Triage of HPV positivity in a high HIV prevalence setting: a prospective cohort study comparing visual triage methods and HPV genotype restriction in Botswana. International Journal of Gynaecology and Obstetrics. 2024; 165: 507–518.

[47] Miranda-Falconi P, Flores-Peña G, Jiménez-Trejo MF, Torres-Paz YE, Reyes-Hernández DO, Estrada-Guzmán JC, et al. Pioneering molecular screening for cervical precursor lesions and cervical cancer in sera. Frontiers in Oncology. 2024; 14: 1483882.

[48] Dartell MA, Rasch V, Iftner T, Kahesa C, Mwaiselage JD, Junge J, et al. Performance of visual inspection with acetic acid and human papillomavirus testing for detection of high‐grade cervical lesions in HIV positive and HIV negative Tanzanian women. International Journal of Cancer. 2014; 135: 896–904.